Frontiers in pharmaceutical nanotechnology

  1. editorImage
  1. Editor: Prof. Dr. Matthias G. Wacker
    Department of Pharmacy
    Faculty of Science
    National University of Singapore

Today, a wide spectrum of nanomedicines is being developed for the diagnosis, prevention and treatment of disease. Recent breakthroughs include the delivery of small molecules, therapeutic proteins or peptides, and great progress has been made in the material design and targeting of nanocarriers to specific tissues or across biological barriers. However, converting the strategies into products is still challenging, and many nanomedicines fail to comply with the market requirements or during the clinical trials.

This thematic issue aims to present recent research in the design, manufacture and testing of nanomedicines. Potential contributions may include, but are not limited to the following topics:

  • Development of drug delivery systems for pharmaceuticals and biopharmaceuticals (small molecules, proteins, nucleic acids)
  • Manufacturing and biomedical aspects of drug product design
  • Strategies and formulations for controlled drug transport across biological barriers
  • Physicochemical aspects of drug product development
  • Novel excipients for drug product design
  • Drug delivery and controlled release systems for systemic and local applications
  • Nanomaterials for therapeutic and diagnostic purposes

This thematic issue is dedicated to Prof. Dr. Jörg Kreuter, a pioneer of this whole research area, whose contributions have been widely recognized. With more than 300 publications, he has shaped pharmaceutical nanotechnology for the last 40 years.

Additional publications coming soon! Download all of the current publications in this thematic issue by clicking on "Issue PDF".

Tungsten disulfide-based nanocomposites for photothermal therapy

  1. Tzuriel Levin,
  2. Hagit Sade,
  3. Rina Ben-Shabbat Binyamini,
  4. Maayan Pour,
  5. Iftach Nachman and
  6. Jean-Paul Lellouche
  • Full Research Paper
  • Published 02 Apr 2019

  • PDF

  • Supp. Info

Beilstein J. Nanotechnol. 2019, 10, 811–822, doi:10.3762/bjnano.10.81

Serum type and concentration both affect the protein-corona composition of PLGA nanoparticles

  1. Katrin Partikel,
  2. Robin Korte,
  3. Dennis Mulac,
  4. Hans-Ulrich Humpf and
  5. Klaus Langer
  • Full Research Paper
  • Published 06 May 2019

  • PDF

  • Supp. Info

Beilstein J. Nanotechnol. 2019, 10, 1002–1015, doi:10.3762/bjnano.10.101

  • Full Research Paper
  • Published 08 Aug 2019

  • PDF

Beilstein J. Nanotechnol. 2019, 10, 1666–1678, doi:10.3762/bjnano.10.162

Doxorubicin-loaded human serum albumin nanoparticles overcome transporter-mediated drug resistance in drug-adapted cancer cells

  1. Hannah Onafuye,
  2. Sebastian Pieper,
  3. Dennis Mulac,
  4. Jindrich Cinatl Jr.,
  5. Mark N. Wass,
  6. Klaus Langer and
  7. Martin Michaelis
  • Full Research Paper
  • Published 14 Aug 2019

  • PDF

  • Supp. Info

Beilstein J. Nanotechnol. 2019, 10, 1707–1715, doi:10.3762/bjnano.10.166

Lipid nanostructures for antioxidant delivery: a comparative preformulation study

  1. Elisabetta Esposito,
  2. Maddalena Sguizzato,
  3. Markus Drechsler,
  4. Paolo Mariani,
  5. Federica Carducci,
  6. Claudio Nastruzzi,
  7. Giuseppe Valacchi and
  8. Rita Cortesi
  • Full Research Paper
  • Published 29 Aug 2019

  • PDF

Beilstein J. Nanotechnol. 2019, 10, 1789–1801, doi:10.3762/bjnano.10.174

  • Full Research Paper
  • Published 19 Sep 2019

  • PDF

Beilstein J. Nanotechnol. 2019, 10, 1902–1913, doi:10.3762/bjnano.10.185

Keep Informed

RSS Feed

Subscribe to our Latest Articles RSS Feed.


Follow the Beilstein-Institut


Twitter: @BeilsteinInst